Williams & Connolly successfully represented Pfizer in three inter partes review proceedings initiated by Pfizer against uniQure biopharma B.V. The challenged claims of the two patents at issue generally relate to gene therapy for hemophilia B. After successfully persuading the Patent Trial & Appeal Board (“PTAB”) to institute trial, Dov Grossman presented oral argument in August 2022. And on November 15, the PTAB ruled in Pfizer’s favor, invalidating all claims of the challenged patents.
The team representing Pfizer includes Dov Grossman, Shaun Mahaffy, Kathryn Kayali, and Michael Liu.
Click here to read Law360’s coverage of the case.